301 related articles for article (PubMed ID: 10796492)
21. Field trials of an asexual blood stage malaria vaccine: studies of the synthetic peptide polymer SPf66 in Thailand and the analytic plan for a phase IIb efficacy study.
Ballou WR; Blood J; Chongsuphajaissidhi T; Gordon DM; Heppner DG; Kyle DE; Luxemburger C; Nosten F; Sadoff JC; Singhasivanon P
Parasitology; 1995; 110 Suppl():S25-36. PubMed ID: 7784126
[TBL] [Abstract][Full Text] [Related]
22. A trial of the synthetic malaria vaccine SPf66 in Tanzania: rationale and design.
Alonso PL; Tanner M; Smith T; Hayes RJ; Schellenberg JA; Lopez MC; Bastos de Azevedo I; Menendez C; Lyimo E; Weiss N
Vaccine; 1994 Feb; 12(2):181-6. PubMed ID: 8147101
[TBL] [Abstract][Full Text] [Related]
23. Safety, immunogenicity and protective effect of the SPf66 malaria synthetic vaccine against Plasmodium falciparum infection in a randomized double-blind placebo-controlled field trial in an endemic area of Ecuador.
Sempértegui F; Estrella B; Moscoso J; Piedrahita L; Hernández D; Gaybor J; Naranjo P; Mancero O; Arias S; Bernal R
Vaccine; 1994 Mar; 12(4):337-42. PubMed ID: 8178556
[TBL] [Abstract][Full Text] [Related]
24. Immune responses to Plasmodium falciparum antigens during a malaria vaccine trial in Tanzanian children.
Alonso PL; Lopez MC; Bordmann G; Smith TA; Aponte JJ; Weiss NA; Urassa H; Armstrong-Schellenberg JR; Kitua AY; Masanja H; Thomas MC; Oettli A; Hurt N; Hayes R; Kilama WL; Tanner M
Parasite Immunol; 1998 Feb; 20(2):63-71. PubMed ID: 9572049
[TBL] [Abstract][Full Text] [Related]
25. Malaria vaccine.
Khurana SK; Talib VH
Indian J Pathol Microbiol; 1996 Dec; 39(5):433-41. PubMed ID: 9002371
[TBL] [Abstract][Full Text] [Related]
26. Malaria vaccine trials: the missing qualitative data.
Ferreira M
Immunol Cell Biol; 1996 Aug; 74(4):301-5. PubMed ID: 8872178
[TBL] [Abstract][Full Text] [Related]
27. Randomised trial of SPf66 vaccine against Plasmodium falciparum malaria in children in southern Tanzania.
Alonzo PL; Smith T; Schellenberg JR; Masanja H; Mwankusye S; Urassa H; Bastos De Azevedo I; Chongela J; Kobero S; Menendez C
Med Trop (Mars); 1995; 55(4 Suppl):41-6. PubMed ID: 8649265
[TBL] [Abstract][Full Text] [Related]
28. Analysis of multiple Plasmodium falciparum infections in Tanzanian children during the phase III trial of the malaria vaccine SPf66.
Beck HP; Felger I; Huber W; Steiger S; Smith T; Weiss N; Alonso P; Tanner M
J Infect Dis; 1997 Apr; 175(4):921-6. PubMed ID: 9086150
[TBL] [Abstract][Full Text] [Related]
29. Insecticide-treated bed nets and curtains for preventing malaria.
Lengeler C
Cochrane Database Syst Rev; 2004; (2):CD000363. PubMed ID: 15106149
[TBL] [Abstract][Full Text] [Related]
30. Safety, tolerability and immunogenicity of new formulations of the Plasmodium falciparum malaria peptide vaccine SPf66 combined with the immunological adjuvant QS-21.
Kashala O; Amador R; Valero MV; Moreno A; Barbosa A; Nickel B; Daubenberger CA; Guzman F; Pluschke G; Patarroyo ME
Vaccine; 2002 May; 20(17-18):2263-77. PubMed ID: 12009282
[TBL] [Abstract][Full Text] [Related]
31. Protective efficacy and safety of radiation-attenuated and chemo-attenuated Plasmodium Falciparum sporozoite vaccines against controlled and natural malaria infection: a systematic review and meta-analysis of randomized controlled trials.
Abuelazm MT; Elzeftawy MA; Kamal MA; Badr H; Gamal M; Aboulgheit M; Abdelazeem B; Abd-Elsalam S; Abouzid M
Infection; 2024 Jun; 52(3):707-722. PubMed ID: 38319556
[TBL] [Abstract][Full Text] [Related]
32. The first field trials of the chemically synthesized malaria vaccine SPf66: safety, immunogenicity and protectivity.
Amador R; Moreno A; Valero V; Murillo L; Mora AL; Rojas M; Rocha C; Salcedo M; Guzman F; Espejo F
Vaccine; 1992; 10(3):179-84. PubMed ID: 1557934
[TBL] [Abstract][Full Text] [Related]
33. [Vaccination against malaria: initial trial with an ant-sporozoite vaccine, (NANP)3-TT (RO 40-2361) in Africa (Bobo-Dioulasso, Burkina Faso)].
Guiguemdé TR; Sturchler D; Ouédraogo JB; Drabo M; Etlinger H; Douchet C; Gbary AR; Haller L; Kambou S; Fernex M
Bull Soc Pathol Exot; 1990; 83(2):217-27. PubMed ID: 2119897
[TBL] [Abstract][Full Text] [Related]
34. An efficacy trial of a malaria vaccine in Gambian infants and comparison with insecticide-treated bednets.
D'Alessandro U
Ann Trop Med Parasitol; 1996 Aug; 90(4):373-8. PubMed ID: 8944081
[TBL] [Abstract][Full Text] [Related]
35. [Current state and problems of the development of malaria vaccine].
Tanabe K
Nihon Rinsho; 1996 Aug; 54(8):2252-60. PubMed ID: 8810805
[TBL] [Abstract][Full Text] [Related]
36. The vaccine is dead--long live the vaccine.
Snounou G; Rénia L
Trends Parasitol; 2007 Apr; 23(4):129-32. PubMed ID: 17300988
[TBL] [Abstract][Full Text] [Related]
37. A randomised, double-blind, controlled vaccine efficacy trial of DNA/MVA ME-TRAP against malaria infection in Gambian adults.
Moorthy VS; Imoukhuede EB; Milligan P; Bojang K; Keating S; Kaye P; Pinder M; Gilbert SC; Walraven G; Greenwood BM; Hill AS
PLoS Med; 2004 Nov; 1(2):e33. PubMed ID: 15526058
[TBL] [Abstract][Full Text] [Related]
38. Mefloquine for preventing malaria in non-immune adult travellers.
Croft AM; Garner P
Cochrane Database Syst Rev; 2000; (3):CD000138. PubMed ID: 10908460
[TBL] [Abstract][Full Text] [Related]
39. Malaria vaccine offers hope. International / Africa.
Vaccine Wkly; 1995 Mar; ():10-1. PubMed ID: 12288959
[TBL] [Abstract][Full Text] [Related]
40. Iron chelating agents for treating malaria.
Smith HJ; Meremikwu M
Cochrane Database Syst Rev; 2003; (2):CD001474. PubMed ID: 12804409
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
